Search clinical trials for: Daratumumab Bortezomib Dexamethasone Dapagliflozin

Total 441 results

Beijing Chao Yang Hospital
Beijing Boren Hospital; Beijing Chuiyangliu Hospital

Not yet recruiting

Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

M-protein Related Cardiac Disease
Air Force Military Medical University, China

Not yet recruiting

Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

Immunoglobulin Light-chain Amyloidosis
Universitätsklinikum Hamburg-Eppendorf
Gemeinsamer Bundesausschuss (G-BA); Staburo GmbH

Recruiting

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)

Multiple Myeloma

Germany
University of Alabama at Birmingham

Recruiting

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Multiple Myeloma

United States
Fondazione Italiana Linfomi - ETS
Janssen-Cilag S.p.A.

Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (FIL_DALYA)

Plasmablastic Lymphoma

Italy
European Myeloma Network
Janssen Pharmaceutica

Active, not recruiting

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Light Chain (AL) Amyloidosis, Stage 3B

Netherlands, Greece, France, Italy
H. Lee Moffitt Cancer Center and Research Institute
Janssen Scientific Affairs, LLC

Active, not recruiting

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
PETHEMA Foundation
Janssen, LP; Adknoma Health Research

Recruiting

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Multiple Myeloma | Non-eligible for Autologous Stem Cell Transplantation (ASCT)

Spain
Intergroupe Francophone du Myelome
Janssen Research & Development, LLC; HOVON - Dutch Haemato-Oncology Association

Active, not recruiting

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)

Multiple Myeloma

Netherlands, France, Belgium
Augusta University
Janssen Scientific Affairs, LLC

Not yet recruiting

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Multiple Myeloma | Renal Failure

United States
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)

Multiple Myeloma

Norway, Denmark, Netherlands, Czechia, Australia, Turkey, Spain, Belgium, Switzerland, France, Greece, Italy, Poland
Janssen Research & Development, LLC

Completed

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, Poland, Ukraine, Germany, Spain, Turkey, Korea, Republic of, Brazil, Russian Federation, Netherlands, Hungary, Sweden, Czechia, Mexico
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
The First Affiliated Hospital of Soochow University

Not yet recruiting

Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf

Completed

Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment (GMMG-DANTE)

Multiple Myeloma

Germany, Greece
National Cancer Institute (NCI)

Completed

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

Head and Neck Cancer

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
National Cancer Institute (NCI)

Completed

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

Head and Neck Cancer | Laryngeal Cancer | Oral Cancer | Carcinoma, Squamous | Pharyngeal Cancer

United States
Janssen Research & Development, LLC

Completed

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China, Taiwan
GlaxoSmithKline

Active, not recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

Multiple Myeloma

Australia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
Peking Union Medical College Hospital
Xian-Janssen Pharmaceutical Ltd.

Active, not recruiting

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Amyloidosis; Systemic

China
Oslo University Hospital
University Hospital of North Norway; Helse Stavanger HF; Haukeland University... and other collaborators

Recruiting

The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study

Multiple Myeloma

Norway
Seoul National University Hospital
Consortium for Improving Survival of Lymphoma

Completed

Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma (BATMAN)

Mantle Cell Lymphoma

Korea, Republic of
Abdullah Khan

Terminated

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Antengene Corporation

Active, not recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (BENCH)

Relapsed or Refractory Multiple Myeloma

China
PETHEMA Foundation

Recruiting

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Refractory Multiple Myeloma

Spain
Singapore General Hospital
Janssen, LP; International Myeloma Foundation

Active, not recruiting

Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

Multiple Myeloma | Myeloma

Singapore
Alexion Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

AL Amyloidosis

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Amyloidosis | Light Chain Deposition Disease (LCDD or MIDD) | Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) | Monoclonal Immunoglobulin Deposition Disease (MIDD)

United States
Jin Lu, MD

Recruiting

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

AL Amyloidosis | Amyloidosis; Systemic

China
Janssen-Cilag International NV

Completed

Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (OPTIMRETREAT)

Multiple Myeloma

France, Poland, Belgium, Germany, Israel, Portugal, Turkey, Finland, Sweden, Netherlands, Norway
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
European Myeloma Network
EMN Research Italy

Active, not recruiting

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Multiple Myeloma

Czechia, Greece, Italy
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Samsung Medical Center

Completed

Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma

Relapsed and/or Refractory Cutaneous T-cell Lymphoma

Korea, Republic of
Tampere University Hospital
Turku University Hospital; Helsinki University Central Hospital; Oulu University... and other collaborators

Completed

Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT

Multiple Myeloma

Finland
Hellenic Society of Hematology
Janssen Pharmaceuticals

Completed

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment (DARE)

Relapsed/Refractory Multiple Myeloma

Greece
Institute of Hematology & Blood Diseases Hospital...

Terminated

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment (BID-PERAL)

Acquired Pure Red Cell Aplasia

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Human Genome Sciences Inc.

Completed

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada, Australia, India
Sun Yat-sen University

Unknown

Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

Multiple Myeloma

China
Sparrow Regional Cancer Center

Unknown

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Multiple Myeloma and Plasma Cell Neoplasm

United States
Celgene

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Multiple Myeloma

Austria, Italy, China, Australia, Spain, United States, Korea, Republic of, Taiwan, Germany, Ireland, Argentina, Brazil, Mexico, Netherlands, Belgium, Czechia, France, Greece, Japan, Poland, Israel, United Kingdom, Norway, Denmark, Finland and more
AbbVie
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, Denmark, France, Germany, Japan
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

Multiple Myeloma in Relapse

France
La Jolla Pharmaceutical Company

Terminated

Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

Multiple Myeloma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
AbbVie
Genentech, Inc.

Completed

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Relapsed/Refractory Multiple Myeloma

United States, Australia, France
Celgene

Active, not recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, United Kingdom
Assistance Publique - Hôpitaux de Paris

Completed

Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy (MYRE)

Chronic Renal Failure With Uremic Nephropathy

France

Search clinical trials for: Daratumumab Bortezomib Dexamethasone Dapagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations